Publication Year

Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus burden and healthcare utilization in United States infants, <1 year of age: Study of nationally representative databases, 2011–2019. J Infect Dis 226(Suppl 2):S184–S194; doi: 10.1093/infdis/jiac155. PMID: 35968879.

Movva N, Suh M, Reichert H, Hitze B, Sendak MP, Wolf Z, et al. 2022. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: A retrospective cohort study of a health system. J Infect Dis 226(Suppl 2):S175–S183; doi: 10.1093/infdis/jiac220. PMID: 35968868.

Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, Nelson CB. 2022. Respiratory syncytial virus (RSV) is the leading cause of United States infant hospitalizations 2009–2019: A study of the National (Nationwide) Inpatient Sample. J Infect Dis 226(Suppl 2):S154–S163; doi: 10.1093/infdis/jiac120. PMID: 35968878.

Rankin DA, Haddadin Z, Lipworth L, Stahl AL, Fryzek J, Suh M, et al. 2022. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. Therapeut Adv Infect Dis 9(July 18):20499361221112171; doi: 10.1177/20499361221112171. PMID: 35875809.

Habib A, Sacks NC, Cool C, Durgapal S, Hughes T, Hernandez J, Phillips G. Trends in hospital admissions and readmissions for patients with MG from U.S. national research databases. Poster presentation, American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, September 2022.

Sacks NC. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Poster presentation, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)Europe, November 2022.

Bonkowsky J, Healey B, Sacks NC, Mclin R, Cyr PL, Sawyer E, Stephen CB, et al. Burden of illness and mortality in adult men with adrenomyeloneuropathy: A retrospective study of real-world data. American Academy of Neurology, Seattle, WA, 2022

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9. PMID: 34331235.

Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL, Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197. PMID: 35343812.

Sacks NC, Healey BE, Raza S, Cyr PL, Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364. PMID: 34807973.